Cargando…

Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial

BACKGROUND: Coagulation abnormalities are involved in the pathogenesis of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). The administration of recombinant human soluble thrombomodulin (rhTM), which has both anti-inflammatory and anticoagulant activities, improves outcomes and respira...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayakawa, Sho, Matsuzawa, Yasuo, Irie, Tamako, Rikitake, Hagino, Okada, Noriaki, Suzuki, Yasuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098285/ https://www.ncbi.nlm.nih.gov/pubmed/27826444 http://dx.doi.org/10.1186/s40248-016-0074-z

Ejemplares similares

Serum oxidative stress in patients with pulmonary Mycobacterium avium complex disease
por: Wakabayashi, Hiroki, et al.
Publicado: (2019)

Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Isshiki, Takuma, et al.
Publicado: (2019)

Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study
por: Awano, Nobuyasu, et al.
Publicado: (2022)

Efficacy of recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis
por: Wang, Baojun, et al.
Publicado: (2020)

The efficacy of recombinant human soluble thrombomodulin (rhsTM) treatment for acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis
por: Kamiya, Hiroyuki, et al.
Publicado: (2020)

Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Horita, Nobuyuki, et al.
Publicado: (2020)

Pharmacokinetics of Recombinant Human Soluble Thrombomodulin in Disseminated Intravascular Coagulation Patients with Acute Renal Dysfunction
por: Hayakawa, Mineji, et al.
Publicado: (2017)

Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

Efficacy of recombinant human soluble thrombomodulin in disseminated intravascular coagulation
por: Yasuda, T, et al.
Publicado: (2010)

Clinical efficacy of recombinant human soluble thrombomodulin in patients with septic disseminated intravascular coagulation
por: Suzuki, Y, et al.
Publicado: (2013)

Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study
por: Abe, Mitsuhiro, et al.
Publicado: (2015)

The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study
por: Yoshihara, Masato, et al.
Publicado: (2015)

Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced DIC
por: Yamakawa, K, et al.
Publicado: (2014)

Coagulofibrinolytic effects of recombinant soluble thrombomodulin in prolonged porcine cardiac arrest
por: Zhang, Boya, et al.
Publicado: (2023)

Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial
por: Arai, Toru, et al.
Publicado: (2020)

Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients
por: Miyoshi, Seigo, et al.
Publicado: (2014)

Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kobayashi, Tetsu, et al.
Publicado: (2020)

Recombinant Human Soluble Thrombomodulin Suppresses Monocyte Adhesion by Reducing Lipopolysaccharide-Induced Endothelial Cellular Stiffening
por: Okamoto, Takayuki, et al.
Publicado: (2020)

Protective Effects of Recombinant Human Soluble Thrombomodulin on Lipopolysaccharide-Induced Acute Kidney Injury
por: Nozaki, Yuji, et al.
Publicado: (2020)

Enhanced effect of recombinant human soluble thrombomodulin by ultrasound irradiation in acute liver failure
por: Hoshino, Kota, et al.
Publicado: (2020)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin
por: Arai, Toru, et al.
Publicado: (2021)

Clinical Impact of Recombinant Soluble Thrombomodulin for Disseminated Intravascular Coagulation Associated with Severe Acute Cholangitis
por: Okuda, Atsushi, et al.
Publicado: (2018)

Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2019)

Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III
por: Nakayama, Satoshi, et al.
Publicado: (2020)

Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors
por: Ouchi, Kota, et al.
Publicado: (2018)

Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model
por: Iba, Toshiaki, et al.
Publicado: (2009)

Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study
por: Yamakawa, Kazuma, et al.
Publicado: (2011)

Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia
por: Ookura, Miyuki, et al.
Publicado: (2018)

Circulating activated protein C levels are not increased in septic patients treated with recombinant human soluble thrombomodulin
por: Arishima, Takuro, et al.
Publicado: (2018)

Factors influencing the effectiveness of recombinant human soluble thrombomodulin on disseminated intravascular coagulation: a retrospective study
por: Asai, Yuki, et al.
Publicado: (2020)

Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura
por: Nakamura, Kensuke, et al.
Publicado: (2016)

Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous Hemodiafiltration
por: Watanabe, Eizo, et al.
Publicado: (2017)

Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2013)

Use of Recombinant Human Soluble Thrombomodulin in Patients with Sepsis-Induced Disseminated Intravascular Coagulation after Intestinal Perforation
por: Tagami, Takashi, et al.
Publicado: (2015)

Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study
por: Kato, Takahiro, et al.
Publicado: (2018)

Recombinant human soluble thrombomodulin is associated with attenuation of sepsis-induced renal impairment by inhibition of extracellular histone release
por: Akatsuka, Masayuki, et al.
Publicado: (2020)

Effects of recombinant human soluble thrombomodulin on neutrophil extracellular traps in the kidney of a mouse model of endotoxin shock
por: Harada, Tatsuhiko, et al.
Publicado: (2023)

Reply to Kobayashi et al.: Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

Recombinant Human-Soluble Thrombomodulin Contributes to Reduced Mortality in Sepsis Patients With Severe Respiratory Failure: A Retrospective Observational Study Using a Multicenter Dataset
por: Yoshihiro, Shodai, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4gedlqd2f2186uha56l8gdqagn